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statin-treAt the recent Scientiﬁc Sessions of the National Lipid Association
in Philadelphia, a lot of attention has been paid to the variation in
presentation of patients with familial hypercholesterolemia. The
phenotypic variation from the disorder is larger among carriers of
the same mutation than between those of different mutations. In
addition to the type of mutation, clearly other genes and environ-
mental factors inﬂuence the expression to a large extent [1]. Early
statin treatment has high efﬁcacy in familial hypercholesterolemia
[2]. Nonetheless, a residual cardiovascular disease risk persists. One
of the greatest present-day challenges is to recognize the statin-
treated patients, who still will suffer from cardiovascular disease.
In the paper published in this issue of Atherosclerosis, Mangili
et al. meticulously phenotyped their patients by examining the
Achilles tendons, searching for xanthomas, and performing CT cor-
onary angiography [3]. Twenty-one patients out of 102 asymptom-
atic patients with treated familial hypercholesterolemia presented
with xanthomas and these patients clearly had more extensive cor-
onary artery disease.
A strong association between xanthomas and cardiovascular
events had been reported in a meta-analysis [4]. In an underpow-
ered analysis of asymptomatic, statin-treated patients with familial
hypercholesterolemia, xanthomas tended to be associated with the
extent of coronary artery disease [5]. The article by Mangili et al.
conﬁrms this relationship. The ﬁndings about the intermediate
atherosclerotic trait are important for future research on the pre-
diction of cardiovascular disease. These ﬁndings emphasize the
need for follow-up and merging of data for meta-analyses to esti-
mate the predictive value of the presence of xanthomas for coro-
nary artery disease. Although statins reduce the size of
xanthomas [6], the studies using CT angiography suggest that the
xanthomas may still be a valid marker of increased cardiovascular
disease risk. It is reassuring that a good physical examination willerosclerosis.2017.04.025.
E.J. SijbrandsXanthomas angive you clues about the cardiovascular risk of your
ated patients with familial hypercholesterolemia. Notably,
Mangili et al. found that the association between xanthomas and
coronary artery disease was independent of other known risk fac-
tors. If this ﬁnding survives future replication efforts, it has pro-
vided the ﬁrst proof that studying xanthomas can be a
worthwhile effort to identify new mechanisms of developing
atheromas.
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